Drugs & Targets FDA grants Fast Track designation for Reqorsa with Keytruda in NSCLC January 07, 2022Vol.48 No.01
Drugs & TargetsFree FDA approves Orencia for prevention of acute graft vs. host disease following unrelated donor HSCT December 17, 2021Vol.47 No.46
Drugs & Targets FDA approves Rituxan plus chemo for pediatric cancer indications December 10, 2021Vol.47 No.45
Drugs & Targets FDA approves FoundationOne CDx as companion diagnostic for BRAF inhibitor therapeutics in melanoma December 10, 2021Vol.47 No.45
Drugs & Targets FDA approves Oncomine Dx Target Test as CDx for Rybrevant December 10, 2021Vol.47 No.45
Drugs & Targets FDA accepts sBLA for BMS’ Reblozyl for priority review in adults with non-transfusion dependent beta thalassemia December 10, 2021Vol.47 No.45
Regulatory News FDA cancels second ODAC in a row as two accelerated approval drugs are yanked by sponsors (and one still dangles) December 03, 2021Vol.47 No.44By Alice Tracey
In Brief Robert Califf receives support from 54 organizations to be commissioner of the FDA December 03, 2021Vol.47 No.44
Drugs & Targets FDA approves Fyarro for malignant perivascular epithelioid cell tumor December 03, 2021Vol.47 No.44
